Li et al. identified the prognostic value of ATXN2L in GC through bioinformatics analysis and experimentally confirmed that blocking EGFR/ATXN2L signaling can reverse oxaliplatin resistance in GC cells and inhibit migration (Lin et al. 2019). The gene discussed is ATXN2L; the disease is gastric cancer.